Skip to main content
. Author manuscript; available in PMC: 2016 Dec 10.
Published in final edited form as: ACS Infect Dis. 2016 Oct 4;2(12):945–957. doi: 10.1021/acsinfecdis.6b00144

Table 3.

Comparative DSM421 and DSM265 activity on P. falciparum and P. vivax.

Assay EC50(μM) Fraction unbound in assay media unbound EC50 (μM) EC50 (μM) Fraction unbound in assay media unbound EC50 (μM)
DSM265 DSM421
Blood-stage: P. falciparum 3D7 in vitro 72 h growth assay 0.0043 0.17a 0.00073 .014 0.5a 0.0070
Blood-stage: P. falciparum 3D7 in vitro 48 h growth assay (PRR) 0.011 0.17a 0.0019 .043 0.5a 0.022
Blood-stage: P. falciparum field isolates, 72 h assay ND ND ND 0.023 0.5a 0.012
Blood-stage: schizont maturation assay P. falciparum Field isolates 0.19 0.003b 0.00057 0.15 0.15b 0.023
Blood-stage: schizont maturation assay P. vivax Field isolates 0.92 0.003b 0.0028 0.18 0.15b 0.027
a

0.5% Albumax II in RPMI-1640;

b

10% human serum in RPMI 1640 or similar media.

c

10% fetal calf serum in DMEM or similar medium;

ND=not determined. For DSM265 data in italics were taken from.18 See Table S8 for protein binding data.